Stem Cell Therapy in Singapore
Advancing Scalable iPSC-Derived Cell Therapy for Diabetes
BetaLife is developing scalable, hypoimmune iPSC-derived islet cell therapies designed to restore natural insulin production, advance insulin independence and reduce the need for chronic immunosuppression in people living with insulin-dependent diabetes.
Who BetaLife Is
BetaLife is a Singapore biotech spin-off from A*STAR's Institute of Molecular and Cell Biology, established to translate pioneering stem cell research into next-generation therapeutic solutions. We are advancing scalable, hypoimmune iPSC-derived islet cell therapies designed to restore natural insulin production and move towards insulin independence for people living with insulin-dependent diabetes.
Combining deep scientific expertise, genomic engineering, iPSC technology and scalable manufacturing capabilities, BetaLife is building an integrated cell replacement platform designed to overcome key challenges in diabetes treatment. Our approach aims to deliver durable, accessible and potentially transformative therapies for people who depend on lifelong insulin management.
The Unmet Need
Diabetes affects hundreds of millions worldwide, with many relying on lifelong insulin therapy. While essential, insulin does not replace lost or impaired insulin-producing pancreatic cells, making cell restoration a significant unmet medical need.
Our Science & Technology
Advancing Cell Therapy Through iPSC Innovation
BetaLife combines advanced stem cell biology, genomic engineering, hypoimmune cell engineering and scalable manufacturing to develop next-generation cell replacement therapies designed to restore insulin production and advance insulin independence for people living with insulin-dependent diabetes.
Cell Replacement Therapy
Restoring Natural Insulin Production Through Cell Replacement
BetaLife is developing iPSC-derived islet cells designed to restore insulin production and move towards insulin independence. Our therapeutic approach aims to replace lost or impaired insulin-producing cells with durable, scalable cell-based therapies.
iPSC Technology Platform
Engineering the Next Generation of iPSC-Based Therapies
Our integrated iPSC platform combines iPSC generation, genomic and hypoimmune engineering, islet cell differentiation and scalable 3D manufacturing to develop consistent, functional cells for advanced, next-generation cell replacement therapies in diabetes.
We welcome partnerships, investment and collaborations to advance next-generation cell therapies and regenerative medicine.
BetaLife is Engineering Next-Generation iPSC-Derived Cell Therapies to Transform Diabetes Treatment and Restore Natural Insulin Production
Advanced iPSC Solutions for Institutions
BetaLife provides iPSC-related products and specialised services to support research institutions, laboratories, biotechnology companies and organisations working in cell biology and regenerative medicine. Our capabilities and cellular resources support research and development, accelerate scientific discovery and enable organisations to advance their cell-based programmes.
Preserve Your Cellular Future with BetaVault
BetaVault is BetaLife's personalised iPSC banking platform, enabling individuals to preserve their own cells as a secure, long-term biological resource for future use. By combining personalised cell banking with BetaLife's expertise in iPSC technology, BetaVault aims to create opportunities for future research, personalised medicine and emerging regenerative healthcare applications.
Extending Our iPSC Expertise to Research and Personalised Cell Banking
BetaLife extends its expertise in iPSC technology beyond therapeutic development, supporting research institutions, biotechnology organisations and individuals through specialised cellular services and personalised iPSC banking. By expanding access to advanced iPSC technologies, BetaLife aims to support scientific research, personalised medicine and future healthcare applications.
